PMC6393887_01
MRI brain. (a) An axial, postcontrast-enhanced, fat-saturated T1-weighted image of the brain shows a 2.0 x 1.0 cm right parietal mass with ill-defined area of enhancement. (b) An axial, contrast enhanced, fat-saturated T1-weighted image of the brain, 3 weeks after therapy with cabozantinib, shows resolution of the prior mass and surrounding enhancement.
CRIU2019-6769017.001.jpg
PMC6393887_01_CRIU2019-6769017.001.jpg
fig1
Three weeks after starting cabozantinib, a repeat MRI brain was obtained for radiation planning and showed complete resolution of the right parietal mass with now encephalomalacia of the area (Figure 1).
CT CAP. (a) and (b) Axial images of CT CAP showed right sided hilar lymphadenopathy and a large left kidney mass. (c) and (d) Axial images of CT CAP showed improvement in right sided hilar lymphadenopathy and reduction in size of left kidney mass, after 8 weeks of therapy with cabozantinib.
CRIU2019-6769017.002.jpg
PMC6393887_01_CRIU2019-6769017.002.jpg
fig2
A CT CAP, obtained 8 weeks after initiation of cabozantinib therapy, showed partial response with reduction in size of mediastinal lymphadenopathy and bilateral renal masses (Figure 2).